Latest studies
- RecruitingPHASE3
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
This study looks at a new medicine called Tozorakimab. We want to see if it can help people in hospital with lung infections who need extra oxygen. The goal is to stop them from getting sicker, like needing a breathing machine, or even dying.
Viral Lung Infection and Acute Respiratory FailureVietnam - Active not recruitingPHASE3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
This study compares a new medicine, Sacituzumab Tirumotecan, with standard chemotherapy for advanced lung cancer. It’s for people whose cancer has specific genetic changes and has already been treated. We're looking to see if the new medicine helps people live longer and keeps their cancer from growing for longer.
Non-small Cell Lung Cancer (NSCLC)Vietnam - RecruitingPHASE3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
This study looks at new treatments for a type of breast cancer called triple-negative. It compares a new drug, Dato-DXd, sometimes with Durvalumab, against standard chemotherapy with Pembrolizumab for patients whose cancer has come back locally or spread.
Breast CancerVietnam - RecruitingPHASE3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
This study looks at a new medicine, vicadrostat, for people with type 2 diabetes, high blood pressure, and heart disease. It aims to see if taking vicadrostat alongside empagliflozin can help reduce heart problems. Half the participants will get the study medicine, and half will get a dummy pill.
Diabetes Mellitus, Type 2HypertensionCardiovascular DiseasesVietnam - RecruitingPHASE2
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
This study is looking into a new medicine called Volrustomig for various advanced cancers, including cervical, head and neck, oesophageal, and mesothelioma. It aims to see how well it works and if it's safe, both on its own and with standard chemotherapy.
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)Vietnam - Recruiting
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
This study tracks the health of people with Gaucher disease over time, whether or not they are receiving treatment. There's also a sub-study for pregnant women with Gaucher disease to see how their pregnancies and babies' health progress. It helps doctors learn more about the condition.
Gaucher DiseaseCerebroside Lipidosis SyndromeGlucocerebrosidase Deficiency DiseaseGlucosylceramide Beta-Glucosidase Deficiency DiseaseVietnam - Active not recruitingPHASE3
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
This study is looking into a new combination treatment (Zibotentan/Dapagliflozin) for chronic kidney disease with high protein levels in the urine. It compares this combination with an existing treatment (Dapagliflozin) to see if it's more effective and safe.
Chronic Kidney Disease With High ProteinuriaVietnam - RecruitingPHASE3
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
This study looks at new drug combinations (Dato-DXd with rilvegostomig) for a type of advanced lung cancer. It compares them to a standard treatment, pembrolizumab, to see if they work better and are safe as a first treatment option.
Non-Small Cell Lung CancerVietnam - RecruitingPHASE3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
This study investigates if a new drug, vicadrostat, combined with empagliflozin, can help adults with heart failure and a weakened heart pump. Participants will take study medications for up to 3.5 years, alongside their usual care.
Heart FailureVietnam - Active not recruitingPHASE2
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
This study explored a new combination of medicines, tepotinib and osimertinib, for people with a specific type of advanced lung cancer. It looked at whether this combination could shrink tumours, was safe, and how the body handled the drugs after their initial treatment stopped working.
Non-small Cell Lung CancerVietnam - Active not recruitingPHASE3
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
This study looks at new treatments for early-stage lung cancer after surgery. It compares new drug combinations against standard care to see if they can stop the cancer from coming back, especially in people with higher risk.
Non-small Cell Lung CancerVietnam - Active not recruitingPHASE3
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
This study is looking at new ways to treat a type of breast cancer that doesn't have certain hormone receptors or HER2 protein, called triple-negative or hormone receptor-low/HER2-negative breast cancer. It tests two different treatment plans using new and existing medicines before and after surgery.
Breast CancerVietnam - RecruitingPHASE3
C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
This study compares two treatments, BEM/RZR and SOF/VEL, for chronic hepatitis C in adults. It's looking to see how well they work and if they are safe. It’s for people who haven't had these types of treatments before and usually have mild or no liver damage.
HEPATITIS C VIRUS CHRONIC INFECTIONHepatitis C, ChronicHepatitis C Virus InfectionHepatitis CVietnam - RecruitingPHASE2
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
This study is testing a new medicine, tozorakimab, for adults with asthma that isn't well-controlled. It's looking at how well different doses work and if they are safe, compared to a dummy treatment.
AsthmaVietnam - Active not recruitingPHASE3
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
This study looks at a new drug, baxdrostat, combined with an existing one, dapagliflozin, for adults with chronic kidney disease and high blood pressure. It aims to see if this combination can slow down kidney disease progression safely.
Chronic Kidney Disease and HypertensionVietnam - RecruitingPHASE3
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
This study is testing a new monthly tablet, MK-8527, to see if it can prevent HIV as effectively as current daily medicine. Researchers want to check its safety and how well people tolerate it, hoping to offer a convenient new way to protect against HIV.
Human Immunodeficiency Virus (HIV)HIV Pre-Exposure ProphylaxisVietnam - Active not recruitingPHASE2
A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
This study looks at new treatments for advanced bladder cancer that can’t be removed by surgery and where standard chemotherapy isn't an option. It tests two drugs, Durvalumab and Olaparib, to see if they are safe and effective.
Urinary Bladder NeoplasmsVietnam - Active not recruitingPHASE3
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
This study is testing a new combination of treatments for adults with advanced lung cancer (NSCLC) that hasn't spread to the brain or spine and doesn't have certain genetic changes. It compares this new treatment to a standard one, hoping it works better.
NSCLCVietnam - Active not recruitingPHASE4
A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission
This study looks at whether people with a type of arthritis called non-radiographic axial spondyloarthritis need to keep taking a medicine called secukinumab to stay well once their symptoms have improved. It compares continuing secukinumab with switching to a dummy treatment.
Non-radiographic Axial SpondyloarthritisVietnam - Active not recruitingPHASE3
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
This study is testing a new medicine called sibeprenlimab for a kidney disease called IgA nephropathy (IgAN). It aims to see if the medicine can reduce protein in the urine and protect kidney function over time, compared to a dummy medicine.
Immunoglobulin A NephropathyVietnam - RecruitingPHASE3
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
This study looks at a new drug, patritumab deruxtecan, for a certain type of advanced breast cancer. It aims to see if this new treatment helps people live longer or stops cancer from growing compared to standard treatments like chemotherapy.
Breast NeoplasmsVietnam - RecruitingPHASE3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
This study is looking at new ways to treat advanced non-small cell lung cancer (a type of lung cancer) that has spread. It compares an experimental drug, rilvegostomig, with a standard drug, pembrolizumab, both given with chemotherapy, to see which works better and is safer.
Non-squamous Non-small Cell Lung CancerVietnam - RecruitingPHASE3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
This study looks for better ways to treat early-stage, high-risk breast cancer. It tests a new targeted therapy, sacituzumab tirumotecan, with other standard treatments to see if it reduces cancer and helps people live longer without the cancer returning.
Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast NeoplasmsVietnam - Active not recruitingPHASE3
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
This study is looking at a new medicine called acalabrutinib. We want to see if adding it to standard treatment (bendamustine and rituximab, or BR) works better than standard treatment alone for people with a type of blood cancer called mantle cell lymphoma that hasn't been treated before.
Lymphoma, Mantle CellVietnam - Active not recruitingPHASE3
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
This study is looking into a new medication called tozorakimab for people with severe COPD who have frequent flare-ups. It aims to see if this treatment can reduce these flare-ups and improve symptoms. Patients will receive either the new medicine or a dummy treatment.
Chronic Obstructive Pulmonary Disease (COPD)Vietnam - Active not recruitingPHASE3
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
This study is testing if two drugs, dabrafenib and trametinib, can help people with a specific type of thyroid cancer (DTC) that has a BRAF V600E gene change, has stopped responding to radioactive iodine, and has progressed after other treatments.
Differentiated Thyroid Cancer (DTC)Vietnam - Active not recruitingPHASE3
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
This study looks at a new, higher dose of macitentan (75mg) for people with pulmonary arterial hypertension (PAH). Researchers want to see if this dose is better than the current 10mg dose at preventing serious health problems or death related to PAH.
Pulmonary Arterial HypertensionVietnam - RecruitingPHASE3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
This study is looking at new ways to treat advanced lung cancer (squamous non-small cell lung cancer) that has spread. It compares two different drug combinations, including a new medicine called rilvegostomig, to see if they can help patients live longer and improve their quality of life.
Non-small Cell Lung CancerVietnam - Active not recruitingPHASE3
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
This study, DAISY, is testing a new treatment called Anifrolumab for adults with Systemic Sclerosis (also known as Scleroderma). We want to see if it's safe and effective compared to a dummy treatment, to help improve symptoms and quality of life.
Systemic SclerosisSclerodermaVietnam - Active not recruitingPHASE3
RZ358 Treatment for Congenital Hyperinsulinism
This study is testing a new medicine, RZ358, for children and adults with congenital hyperinsulinism (CHI). This condition causes very low blood sugar. The study will see how well RZ358 works to control blood sugar and if it's safe, compared to current treatments alone.
Congenital HyperinsulinismVietnam - Active not recruitingPHASE3
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
This study looks at combining a drug called osimertinib with chemotherapy for a type of lung cancer. It wants to see if this combination works better than osimertinib alone for patients with a specific genetic change in their cancer, hoping to delay the cancer getting worse.
Non-Small Cell Lung CancerVietnam - RecruitingPHASE3
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study looks at new treatments for a type of lung cancer where standard treatment has stopped working. It compares a drug called Dato-DXd, alone or with osimertinib, against usual chemotherapy to see which helps patients live longer without their cancer getting worse.
Metastatic Non-small Cell Lung CancerVietnam - Active not recruitingPHASE3
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
This study is for people with a type of lung cancer that can't be removed by surgery. It tests new drug combinations (Durvalumab with Oleclumab, or Durvalumab with Monalizumab) after standard treatment to see if they can help stop the cancer from coming back or getting worse.
Non-Small Cell Lung CancerVietnam - Not yet recruitingPHASE3
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
This study is looking at a new medicine called Elecoglipron for people with certain types of heart failure. It compares Elecoglipron to a dummy medicine (placebo) to see if it helps improve heart health outcomes for adults already taking other heart failure medications, including dapagliflozin.
Heart Failure With Preserved Ejection Fraction (HFpEF)Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)Vietnam - Active not recruitingPHASE2
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
This study looks at a new combination of two drugs, osimertinib and savolitinib, for people with a certain type of advanced lung cancer. It's for patients whose cancer has grown worse after already taking osimertinib, to see if the new combination can help.
CarcinomaVietnam - Active not recruitingPHASE3
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
This study looks at a drug called osimertinib for people with a certain type of early-stage lung cancer after surgery. We want to see if it helps prevent the cancer from coming back compared to a dummy drug (placebo).
Non-Small Cell Lung CancerVietnam - RecruitingPHASE3
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
This study is looking at new treatments for advanced bile duct cancer that has a specific marker called HER2. We want to see if these new medicines work better and are safer than standard treatments for patients who haven't had treatment for their advanced cancer before.
Biliary Tract CancerVietnam - RecruitingPHASE3
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
This study is testing a new medicine, nerandomilast, for people with systemic sclerosis. It aims to see if the medicine can improve symptoms and slow the disease. Adults with systemic sclerosis might be able to join this study.
Systemic SclerosisVietnam - Active not recruitingPHASE3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
This study looks at the long-term safety and effects of a treatment called iptacopan for primary IgA Nephropathy, a kidney condition. It's for people who have already been in earlier studies for this medication and want to continue receiving it while more information is gathered.
Primary IgA NephropathyVietnam - Active not recruitingPHASE3
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
This study looks at a new drug, AZD0780, for people with heart disease or who are at risk of it, and who have high 'bad' cholesterol (LDL-C). We want to see if AZD0780 safely lowers this cholesterol.
Cardiovascular DiseaseVietnam - RecruitingPHASE2
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
This study is testing a new medicine, AZD6793, for people with moderate to very severe COPD. It will compare different doses of the medicine against a dummy pill to see if it helps and is safe.
Chronic Obstructive Pulmonary Disease (COPD)Vietnam - Active not recruitingPHASE2
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
This study is testing a new medicine, AZD7798, for people with moderate to severe Crohn's disease. We want to see if it's safe and helps improve symptoms compared to a dummy medicine.
Moderate to Severe Crohn's DiseaseVietnam - Not yet recruitingPHASE3
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
This study looks at a new medicine called elecoglipron for people with long-term kidney disease. We want to see if it helps improve health compared to a dummy pill (placebo). Participants will also be taking existing kidney disease treatments like dapagliflozin. It's a large study, involving many people to get clear results.
Chronic Kidney DiseaseVietnam - Active not recruitingPHASE3
AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.
This study looks at a new drug (AZD9291) for people with a certain type of lung cancer (non-small cell lung carcinoma, stages IB-IIIA). It's for patients who have had surgery to remove their tumour, with or without chemotherapy. We want to see if AZD9291 can help prevent the cancer from coming back.
Stage IB-IIIA Non-small Cell Lung CarcinomaVietnam - RecruitingPHASE3
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy
This study looks at a new medicine called obrixtamig for advanced small cell lung cancer. It compares obrixtamig plus standard treatment against standard treatment alone to see if it helps people live longer. It also tests a device to measure a cancer marker.
Small Cell Lung Cancer (SCLC)Extensive-stage Small Cell Lung Cancer (ES-SCLC)Vietnam - Active not recruitingPHASE3
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
This study looks at a new way to treat muscle-invasive bladder cancer using a drug called Durvalumab alongside standard chemotherapy. It aims to see if this combination, given before and after surgery, can improve treatment outcomes and safety for patients.
Muscle Invasive Bladder CancerVietnam - RecruitingPHASE3
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
This study looks at a new drug called anifrolumab for adults with muscle conditions like polymyositis or dermatomyositis. Researchers want to see if it's safe and helps improve symptoms when added to their usual treatment.
Polymyositis, DermatomyositisVietnam - Recruiting
Hospitalised COVID-19 Patients Cohort Study in the EuCARE Project
This study looks at hospitalised COVID-19 patients across the world. Researchers want to understand how different types of the virus and vaccination affect how ill people get and how they recover. They're collecting patient information and some blood samples to learn more.
COVID-19Vietnam - Active not recruitingPHASE3
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
This study is testing new treatments for liver cancer (hepatocellular carcinoma) in people who have had their cancer removed but are at high risk of it coming back. It compares a drug called durvalumab, alone or with bevacizumab, against a dummy treatment (placebo) to see if they can prevent the cancer from returning.
Hepatocellular CarcinomaVietnam - RecruitingPHASE3
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
This study looks at new drug combinations for stomach or food pipe cancer that has spread. It compares an experimental treatment with standard care, aiming to find better ways to treat patients whose cancer has specific features.
Gastric CancerGastroesophageal Junction CancerVietnam